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Background: Oligodendroglial tumors are chemosensitive, with two-thirds of patients responding to PCV
combination chemotherapy with procarbazine, lomustine (CCNU) and vincristine. Temozolomide (TMZ), a
new alkylating and methylating agent has shown high response rates in recurrent anaplastic astrocytoma. We
investigated this drug in recurrent oligodendroglial tumors (OD) and mixed oligoastrocytomas (OA) after
prior PCV chemotherapy and radiation therapy.
Patients and methods: In a prospective non-randomized multicenter phase II trial patients were treated with
TMZ 150 mg/m2 on days 1–5 in cycles of 28 days for 12 cycles. Eligible patients had a recurrence after prior
PCV chemotherapy, with measurable and enhancing disease as shown by magnetic resonance imaging.
Pathology and all responses were centrally reviewed.
Results: Thirty-two eligible patients were included. In four patients the pathology review did not confirm the
presence of an OD or OA. Twelve of 24 patients [50%, 95% confidence interval (CI) 29% to 71%] evaluable
for response to first-line PCV chemotherapy had responded to PCV. Temozolomide was in general well
tolerated; the most frequent side-effects were hematological. One patient discontinued treatment due to
toxicity. In seven of 28 patients (25%, 95% CI 11% to 45%) with histologically confirmed OD an objective
response to TMZ was observed. Median time to progression for responding patients was 8.0 months. After
6 and 12 months from the start of treatment, 29% and 11% of patients, respectively, were still free from
progression.
Conclusions: TMZ may be regarded as the preferred second-line treatment in OD after failure of PCV
chemotherapy. Further studies on TMZ in OD are indicated.
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Introduction
Although 60–70% of patients with oligodendroglial (OD) tumors
respond to PCV chemotherapy [procarbazine, lomustine (cyclo-
hexylchloroethylnitrosourea; CCNU) and vincristine] [1, 2],
most responding patients relapse within 12–18 months [1, 3, 4].
For these patients second-line chemotherapy is often the only
remaining treatment option. Besides, although PCV in general is
considered to be well tolerated, CCNU induces a cumulative
myelosuppression that frequently requires dose reductions and
delays, and discontinuation of treatment before the intended six
cycles of treatment have been given. Nausea and weight loss are
other side-effects that limit treatment in a significant number of
patients. New active agents and treatment regimens that do not
inversely affect quality of life are therefore necessary.
Temozolomide (TMZ) is a new oral alkylating and methylating
agent, which has shown good tolerance and promising activity in
astrocytic tumors. A large phase II trial on first- and second-line
chemotherapy with temozolomide in 162 patients mainly with
recurrent anaplastic astrocytoma showed an objective response
rate of 35% [5]. Because of these results we initiated two
European Organisation for Research and Treatment of Cancer
(EORTC) studies in recurrent OD tumors after radiation therapy,
one investigating TMZ as first-line chemotherapy and the other
as second-line chemotherapy. Here we present the results of the
EORTC 26972 study which investigated second-line chemo-
therapy with TMZ.
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Patients and methods
Patients who were eligible for this study met the following criteria: (i) recur-
rent or progressive OD or mixed oligoastrocytomas (OA) after radiation
therapy and PCV chemotherapy (either adjuvant or at first recurrence);
(ii) measurable disease requiring a contrast enhancing lesion with a diameter
of ≥1 cm on magnetic resonance imaging (MRI) or computed tomography
(CT) scan; (iii) adequate hematological, renal and hepatic function; (iv) World
Health Organisation (WHO) performance status of 0, 1 or 2; and (v) written
informed consent from the patient. Patients undergoing surgery for the
present recurrence were eligible provided they had measurable disease
(enhancing lesions with a diameter >1cm) on imaging obtained within 3 days
of surgery. Patients were included based on the diagnosis made by the local
pathologist, with subsequent central histology review (J.M.K.). Prior to the
activation of the study all centers required approval of their ethics committee.
The primary end point of the study was response. Secondary end points
included toxicity, estimation of time to tumor progression (TTP), overall sur-
vival (OS) and response duration. Response rate and 95% confidence interval
(CI) were calculated by pooling the complete response (CR) and partial
response (PR) patients. Time to tumor progression and OS were measured
from the start of chemotherapy. Overall survival was measured until the date
of death or otherwise at the last follow-up examination. Time to tumor progres-
sion was measured until the first sign of radiological or clinical progression
appeared (whichever came first) or otherwise the date of the last follow-up
visit. Overall survival and TTP were estimated using the Kaplan–Meier
method [6].
Patients were registered at the EORTC Data Center in Brussels according
to the two stage Minimax Simon Design [7]. As a first step, 19 patients were
entered. If no response was observed in this group the study would be
stopped. One responding patient in this cohort assures, with 95% power and a
type I error of 10%, that a minimal response rate of 5% was reached and in
that case 16 more patients would be registered in order to evaluate if the true
response rate is 25%. If so, the drug would be recommended for further
research in a phase III study.
Patients were treated with TMZ 150 mg/m2 on days 1–5, in cycles of
28 days for a maximum of 12 cycles. To avoid treatment heterogeneity no
dose increase to 200 mg/m2 was foreseen. Dose reductions were made as pre-
viously described [5]. Hematological parameters were assessed at baseline
and on days 21 and 28 of each cycle. Electrolytes, renal and hepatic function
were assessed at baseline and on day 28 of each cycle. The primary end point
of the study was response to treatment. Response was evaluated every two
cycles for the first six cycles, thereafter at every three cycles. Response was
measured according to the criteria of Macdonald et al. [8]. Scans of all
patients in which a response (CR or PR) was reported (either to first-line PCV
or to second-line TMZ) were centrally reviewed. Toxicity was assessed accord-
ing to National Cancer Institute-Common Toxicity Criteria (NCI-CTC),
December 1994 version.
Results
Thirty-five patients were enrolled by 10 institutions from April
1998 to February 2000. Three patients were not eligible: one
patient was registered after the start of treatment, one patient did
not have measurable disease and one was subsequently diag-
nosed with radiation necrosis. The main patient and pretreatment
characteristics of those that were eligible are summarized in
Table 1. Of the 24 patients evaluable for response to prior PCV
chemotherapy, 12 had responded to PCV: five CRs and seven
PRs (objective response rate to PCV 50%, 95% CI 29% to 71%).
At central pathology review four patients were diagnosed with a
non-oligodendroglial tumor: pure astrocytic tumors (three
patients) and pilocytic astrocytoma (one patient). At the time of
this analysis 24 patients have died and all but one have progressed.
A total of 176 cycles were administered (median, five cycles;
range 1–16). Treatment was in general well tolerated. In 84%
of patients treatment was delivered at >90% of the intended
dose intensity. Only five cycles were dose reduced (2.8%; three
patients) and 23 cycles (13.1%; 11 patients) were dose delayed
(but in 14 cycles/seven patients this was not related to toxicity).
Grade 3/4 nausea and/or vomiting was observed in three patients
(four cycles), and in subsequent cycles was easily managed with
prophylactic anti-emetics. In two patients (three cycles) treat-
ment was complicated by a grade 3 granulocytopenia and
thrombocytopenia. One patient developed grade 3 dysphagia and
esophagitis, which did not recur despite continuation of treatment
at the same dose level. One patient discontinued treatment because
of prolonged thrombocytopenia, with subsequent uneventful
recovery. In another patient with a borderline performance status
at the start of treatment, TMZ was discontinued after five cycles
because of a lack of clinical improvement in spite of a radio-
logical partial response.
Seven patients responded to TMZ: a response rate of 22%
(7/32; 95% CI 9% to 40%) in all eligible patients. In patients with
verified oligodendroglial pathology the response rate was 25%
(7/28; 95% CI 11% to 45%). In these patients the median TTP
was 3.7 and 8.0 months in responding patients (CR and PR). At 6
and 12 months, respectively, 29% and 11% of patients were still
free from progression; the median overall survival in this group
Table 1. Characteristics of eligible patients
CR, complete response; PCV, procarbazine, lomustine and 
vincristine; PD, progressive disease; PR, partial response; SD, 
stable disease; WHO PS, World Health Organization 
performance status.
No. of patients 32
Age, years
Median 43.6
Range 27–56
WHO PS at start of treatment
0 8
1 12
2 12
Histology (at central review)
Oligodendroglioma 17
Oligoastrocytoma 11
Other 4
Interval since prior PCV chemotherapy
Median, months (range) 6.5 (1–55)
Response to prior PCV chemotherapy 12
CR + PR 10
SD + PD 2
Not evaluable adjuvant 8
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was 12.3 months. Of the 24 patients who were evaluable for
response to PCV, four responded to TMZ: three of 12 responders
to PCV responded to TMZ.
Discussion
This is the first series on second-line chemotherapy with TMZ in
recurrent OD using strict criteria for response including central
response review and central pathology review. We observed a
response rate of 25% in patients in which the central pathology
review confirmed the presence of an OD tumor. In this study,
24 patients had been evaluable for response to first-line PCV
chemotherapy; 12 (50%) of them had responded to PCV. This is
somewhat less than observed in historical series in which 60–70%
response rates were reported [1, 3]. In this small number of
patients, no apparent difference was noted in response rate to
TMZ between responders to first-line PCV and the total study
population.
As noted before, treatment with TMZ was well tolerated [5, 9].
The toxicity of this oral treatment was mild and 85% of the treat-
ment cycles were administered at the intended dose intensity.
Furthermore, most of the dose delays were due to non-medical
reasons. The only grade 4 treatment-related toxicity observed
was vomiting, which was easily managed in subsequent cycles
with anti-emetics. All grade 3 toxicities resolved without
sequelae. Only one patient had to discontinue treatment for
(reversible) toxicity (thrombocytopenia).
Our results are consistent with the response rate to TMZ
observed in patients with recurrent anaplastic astrocytoma and
mixed OA after prior radiation therapy and chemotherapy [5, 10].
Two other series have investigated second-line TMZ chemo-
therapy in recurrent OD, but in less stringent trials. In a retro-
spective multicenter series, van den Bent et al. [9] reported an
objective response rate of 26%, with 44% and 27% remaining
free from progression at 6 and 12 months, respectively. In a pro-
spective single center trial, Chinot et al. [11] observed a higher
response rate (44%), but with similar percentages of patients
remaining free from progression at 6 and 12 months (51% and 24%,
respectively). These studies differ though in their response rate
to prior PCV chemotherapy, suggesting an important selection
bias. In the present study, 50% of patients responded to first-
line PCV chemotherapy, whereas in the study by Chinot et al.
[11], 83% of patients had responded to PCV. The latter response
rate is remarkable, being superior to the ∼65% response rate of
OD to PCV observed both in this and center other studies [1, 3, 12].
This difference appears to be due to the exclusion of patients pro-
gressive under PCV chemotherapy in the latter study (O. Chinot,
personal communication, 2002). Whether indeed a relationship
between response to PCV and response to TMZ exists remains to
be established. Two previous studies did not find a clear correlation
between response to PCV and response to TMZ [9, 11].
One of the problems faced by studies on OD is the fact that
criteria for its diagnosis are poorly defined and poorly reproduc-
ible, and they have been widened to include less typical cases due
to the reported chemosensitivity of OD [13]. As a consequence,
patient selection is likely to affect outcome in trials on chemo-
therapy in OD tumors. This might be reflected in the slightly
lower response rate to PCV in our study as compared with histor-
ical controls. Recent studies have shown that, in particular, OD
with combined loss of the short arm of chromosome 1 (1p) and
the long arm of chromosome 19 (19q) are sensitive to PCV
chemotherapy, with 95–100% of patients responding to PCV [14,
15]. Approximately 55–70% of OD tumors do have combined
loss of 1p/19q. Thus, genetic testing may allow a better identifi-
cation of OD tumors that are likely to respond to chemotherapy.
Data on other second-line treatment regimens in OD tumors
are limited. Cisplatin/etoposide [16], paclitaxel [17], irinotecan
[18] and carboplatin [19] have all shown some activity in second-
line treatment of OD in small phase II studies. Carboplatin treat-
ment was complicated by significant myelosuppression. In brain
tumor patients the use of both paclitaxel and irinotecan is com-
plicated because of interactions with many anti-epileptic drugs
through cytochrome P450 induction. Currently available data
suggest that TMZ may provide better results as second-line treat-
ment in OD tumors. Because of ease of oral administration, good
tolerance to TMZ and absence of interactions with anti-epileptic
drugs, TMZ is therefore to be regarded as the drug of choice for
progressive OD tumors during or after PCV chemotherapy. How-
ever, as only a limited number of patients respond or remain stable
for a more prolonged period of time, further improvement of
second-line treatment is clearly indicated.
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